Jeffrey J. Hessekiel
Net Worth

Last updated:

What is Jeffrey J. Hessekiel net worth?

The estimated net worth of Mr. Jeffrey J. Hessekiel is at least $50,266,108 as of 29 Nov 2024. He owns shares worth $18,246,655 as insider, has earned $23,767,263 from insider trading and has received compensation worth at least $8,252,190 in Exelixis, Inc..

What is the salary of Jeffrey J. Hessekiel?

Mr. Jeffrey J. Hessekiel salary is $916,910 per year as Executive Vice President, Gen. Counsel & Sec. in Exelixis, Inc..

How old is Jeffrey J. Hessekiel?

Mr. Jeffrey J. Hessekiel is 56 years old, born in 1969.

What stocks does Jeffrey J. Hessekiel currently own?

As insider, Mr. Jeffrey J. Hessekiel owns shares in one company:

Company Title Shares Price per share Total value
Exelixis, Inc. (EXEL) Executive Vice President, Gen. Counsel & Sec. 486,059 $37.54 $18,246,655

What does Exelixis, Inc. do?

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

EXEL logo
EXEL
Exelixis, Inc.
$37.54

Jeffrey J. Hessekiel insider trading

Exelixis, Inc.

Mr. Jeffrey J. Hessekiel has made 37 insider trades between 2016-2024, according to the Form 4 filled with the SEC. Most recently he sold 60,000 units of EXEL stock worth $2,200,200 on 29 Nov 2024.

The largest trade he's ever made was exercising 249,692 units of EXEL stock on 8 Sep 2020. As of 29 Nov 2024 he still owns at least 486,059 units of EXEL stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 60,000 $36.67 $2,200,200
Option
Common Stock 129,314 $18.8 $2,431,103
Option
Option (right to buy) 129,314 $18.8 $2,431,103
Sale
Common Stock 50,000 $34.13 $1,706,500
Sale
Common Stock 25,000 $28.39 $709,750
Sale
Common Stock 25,000 $26.38 $659,500
Sale
Common Stock 20,000 $25.79 $515,800
Option
Option (right to buy) 20,000 $24.41 $488,200
Option
Common Stock 20,000 $24.41 $488,200
Sale
Common Stock 80,000 $25.97 $2,077,600
Option
Common Stock 80,000 $24.41 $1,952,800
Option
Option (right to buy) 80,000 $24.41 $1,952,800
Sale
Common Stock 25,000 $23.01 $575,250
Sale
Common Stock 25,000 $22.06 $551,500
Sale
Common Stock 25,000 $22.01 $550,250
Option
Option (right to buy) 55,710 $14.74 $821,165
Option
Common Stock 55,710 $14.74 $821,165
Sale
Common Stock 55,710 $19.63 $1,093,587
Option
Common Stock 13,930 $14.74 $205,328
Option
Option (right to buy) 13,930 $14.74 $205,328
Sale
Common Stock 38,930 $20.01 $778,989
Option
Common Stock 27,860 $14.74 $410,656
Option
Option (right to buy) 27,860 $14.74 $410,656
Sale
Common Stock 77,860 $17.13 $1,333,742
Sale
Common Stock 13,283 $22 $292,226
Sale
Common Stock 4,717 $22 $103,774
Sale
Common Stock 18,000 $20 $360,000
Sale
Common Stock 5,117 $22.03 $112,728
Sale
Common Stock 12,883 $22.02 $283,684
Sale
Common Stock 18,000 $25.03 $450,540
Option
Common Stock 50,000 $3.64 $181,750
Option
Option (right to buy) 30,000 N/A N/A
Option
Option (right to buy) 30,000 $7.27 $218,100
Option
Common Stock 30,000 $7.27 $218,100
Option
Common Stock 39,742 $7.27 $288,924
Option
Option (right to buy) 39,742 $7.27 $288,924
Sale
Common Stock 39,742 $7.27 $288,924
Option
Common Stock 10,258 $7.27 $74,576
Sale
Common Stock 10,258 $7.27 $74,576
Option
Option (right to buy) 10,258 $7.27 $74,576
Option
Option (right to buy) 20,000 $7.27 $145,400
Option
Common Stock 20,000 $7.27 $145,400
Sale
Common Stock 20,000 $7.27 $145,400
Option
Common Stock 249,692 $4.06 $1,012,501
Option
Option (right to buy) 249,692 $4.06 $1,012,501
Option
Option (right to buy) 25,000 $1.7 $42,500
Option
Common Stock 25,000 $1.7 $42,500
Sale
Common Stock 38,006 $27.09 $1,029,583
Option
Common Stock 38,006 $27.09 $1,029,583
Option
Option (right to buy) 38,006 $27.09 $1,029,583
Option
Option (right to buy) 25,000 $26.04 $651,000
Option
Common Stock 25,000 $26.04 $651,000
Sale
Common Stock 25,000 $26.04 $651,000
Sale
Common Stock 30,000 $1.9 $57,000
Option
Common Stock 30,000 $1.9 $57,000
Option
Option (right to buy) 30,000 $1.9 $57,000
Sale
Common Stock 75,000 $1.7 $127,500
Option
Option (right to buy) 75,000 $1.7 $127,500
Option
Common Stock 75,000 $1.7 $127,500
Option
Common Stock 20,000 $1.7 $34,000
Sale
Common Stock 20,000 $1.7 $34,000
Option
Option (right to buy) 20,000 $1.7 $34,000
Sale
Common Stock 1,943 $19.91 $38,685
Sale
Common Stock 1,116 $19.51 $21,773
Sale
Common Stock 11,759 $19.12 $224,832
Sale
Common Stock 65,000 $20.71 $1,346,150
Sale
Common Stock 20,000 $22.36 $447,200
Option
Option (right to buy) 25,000 $1.7 $42,500
Option
Common Stock 25,000 $1.7 $42,500
Option
Option (right to buy) 25,000 $24.32 $608,000
Sale
Common Stock 25,000 $24.32 $608,000
Option
Common Stock 25,000 $24.32 $608,000
Option
Common Stock 2,302 $1.9 $4,374
Sale
Common Stock 2,302 $1.9 $4,374
Option
Option (right to buy) 2,302 $1.9 $4,374
Sale
Common Stock 6,884 $21.02 $144,702
Option
Common Stock 55,000 $1.7 $93,500
Sale
Common Stock 23,787 $20.54 $488,585
Option
Option (right to buy) 55,000 $1.7 $93,500
Option
Option (right to buy) 100,000 $7.27 $727,000
Option
Common Stock 100,000 $7.27 $727,000
Sale
Common Stock 100,000 $23.08 $2,308,300
Sale
Common Stock 59,482 $23.05 $1,371,060
Option
Option (right to buy) 200,000 $1.7 $340,000
Option
Common Stock 200,000 $1.7 $340,000

Exelixis key executives

Exelixis, Inc. executives and other stock owners filed with the SEC: